Patents Issued in September 5, 2024
-
Publication number: 20240293524Abstract: The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.Type: ApplicationFiled: March 28, 2024Publication date: September 5, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Renzo ALFINI, Roberta Di Benedetto, Francesca Micoli, Allan James Saul
-
Publication number: 20240293525Abstract: The present invention relates to attenuated African Swine Fever viruses. The attenuated viruses protect pigs against subsequent challenge with virulent virus. The present invention also relates to the use of such attenuated viruses to treat and/or prevent African Swine Fever. The invention also relates to EP402R proteins of African Swine Fever virus comprising particular amino acid substitutions, as well as polynucleotides encoding such proteins and African Swine Fever viruses comprising such proteins.Type: ApplicationFiled: March 5, 2021Publication date: September 5, 2024Inventors: Linda Dixon, Ana Reis, Anusyah Rathakrishnan, Simon Davis, Yuan Jenq Lui, Shinji Ikemizu
-
Publication number: 20240293526Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (GP) and/or the matrix protein 40 (VP40) and/or the nucleoprotein (NP) of a virus of the genus Ebolavirus or Marburgvirus or a fragment, variant or derivative thereof. Additionally, the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (GP) and/or the matrix protein 40 (VP40) and/or the nucleoprotein (NP) of a virus of the genus Ebolavirus or Marburgvirus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Ebolavirus or Marburgvirus infections.Type: ApplicationFiled: January 30, 2024Publication date: September 5, 2024Applicant: CureVac SEInventors: Susanne RAUCH, Edith JASNY
-
Publication number: 20240293527Abstract: The present invention relates to deoptimized Yellow Fever viruses and their uses for the treatment of various forms of malignant tumors, and as vaccines against Yellow Fever. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain.Type: ApplicationFiled: July 7, 2022Publication date: September 5, 2024Applicant: Codagenix Inc.Inventors: John Robert Coleman, Steffen Mueller, Ying Wang, Chen Yang
-
Publication number: 20240293528Abstract: Described are methods of treating human papillomavirus (HPV) type 16- or HPV type 18-related High-grade Squamous Intraepithelial Lesion (HSIL) of the cervixType: ApplicationFiled: March 1, 2024Publication date: September 5, 2024Inventors: Kimberly A. Kraynyak, Jean D. Boyer, Matthew P. Morrow, Prakash Bhuyan
-
Publication number: 20240293529Abstract: Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.Type: ApplicationFiled: May 17, 2024Publication date: September 5, 2024Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Maria A. CROYLE, Stephen Clay SCHAFER
-
Publication number: 20240293530Abstract: Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.Type: ApplicationFiled: January 3, 2024Publication date: September 5, 2024Inventors: Sarathi BODDAPATI, Anushree HERWADKAR, Jason WONG, Yen-Huei LIN, Gale SMITH, Jing-Hui TIAN
-
Publication number: 20240293531Abstract: Described herein are SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.Type: ApplicationFiled: April 6, 2021Publication date: September 5, 2024Applicant: Valneva Austria GmbHInventors: Andreas Meinke, Michael Möhlen, Robert Schlegl, Jürgen Heindl-Wruss
-
Publication number: 20240293532Abstract: A replication-competent adenovirus type 4 (Ad4) modified to express the SARS-COV-2 spike protein is described. The genome of the recombinant Ad4 is modified to have a deletion of at least a portion of the adenovirus E3 region to accommodate insertion of the spike protein coding sequence. Administration of the recombinant Ad4 to the upper respiratory tract elicits mucosal immunity, which is important for protection against SARS-COV-2 infection and for preventing transmission of the virus.Type: ApplicationFiled: January 14, 2022Publication date: September 5, 2024Applicant: The U.S.A., as Represented by The Secretary, Department of Health and Human ServicesInventor: Mark Connors
-
Publication number: 20240293533Abstract: The present invention provides a recombinant measles virus useful as a live vaccine against COVID-19 and a vector used for production of the recombinant measles virus. That is, the present invention relates to a recombinant measles virus having a gene encoding a protein of the coronavirus SARS-COV-2 inserted between the N gene region and the P gene region in a measles virus genome; the recombinant measles virus in which the protein is a spike protein of SARS-COV-2 or a partial protein thereof; and a DNA in which a gene encoding a protein of SARS-COV-2 is inserted in a region ranging from the 1,686th base to the 1,694th base of a base sequence set forth in SEQ ID NO: 2.Type: ApplicationFiled: May 10, 2021Publication date: September 5, 2024Inventors: Misako Yoneda, Chieko Kai
-
Publication number: 20240293534Abstract: The disclosure provides SARS-CoV-2 mRNA vaccines, comprising a double proline mutation at positions K986 and V987, and an additional substitution D428N that introduces an N-glycosylation site, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: June 13, 2022Publication date: September 5, 2024Applicant: ModernaTX, Inc.Inventor: Guillaume Stewart-Jones
-
Publication number: 20240293535Abstract: The present invention relates to a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.Type: ApplicationFiled: January 18, 2022Publication date: September 5, 2024Applicant: GlaxoSmithKline Biologicals SAInventors: Johann MOLS, Marie TOUSSAINT
-
Publication number: 20240293536Abstract: The present invention relates to a porcine bivalent subunit vaccine composition in a single dose. The porcine bivalent subunit vaccine composition includes porcine bivalent antigen, CpG adjuvant and a dual phase adjuvant. The porcine bivalent antigen consists of a classical swine fever virus (CSFV)-E2 recombinant protein and a porcine circovirus type 2 (PCV2)-ORF2 recombinant protein, both of which are produced by a mammalian cell expression system. The porcine bivalent subunit vaccine composition in a single dose can confer effectively immune protection against CSFV and PCV2 via a single vaccination without boost vaccination.Type: ApplicationFiled: December 22, 2023Publication date: September 5, 2024Applicant: National Pingtung University Of Science And TechnologyInventors: Hso-Chi Chaung, Wen-Bin Chung, Yen-Li Huang, Chi-Chih Chen, Yu-Chieh Chen
-
Publication number: 20240293537Abstract: An amphiphilic imiquimod-grafted lauryl ?-polyglutamate is prepared by adopting a method comprising the following steps: (1) dispersing ?-polyglutamic acid in an aprotic solvent in an anhydrous atmosphere, then adding a catalyst N,N-dimethylformamide, adding dropwise a chlorinating agent under stirring, and keep reaction of the mixture for 10-40 hours; (2) adding imiquimod, liposoluble alcohol and an acid-binding agent into the solution obtained in the step (1) after reaction, and reacting for 42-54 hours; and (3) after purification, obtaining an amphiphilic imiquimod-grafted lauryl ?-polyglutamate material.Type: ApplicationFiled: November 17, 2021Publication date: September 5, 2024Inventors: Wenzhu YIN, Jinqiu ZHANG, Mingxu ZHOU, Yu LU
-
Publication number: 20240293538Abstract: The present invention relates to compositions and methods for manufacturing an adjuvant comprising a saponin using a microfluidic device and to aspects thereof.Type: ApplicationFiled: May 13, 2024Publication date: September 5, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Pol HARVENGT, Philippe JEHOULET, Loic LE GOURRIEREC, Demostene SIFAKAKIS, Laurent STRODIOT
-
Publication number: 20240293539Abstract: A method to produce immunoglobulin preparations against viral infection in humans spreading via respiratory route is provided. The method comprises the steps of immunizing dairy cows during a third trimester of at least a first gestation period with antigen proteins derived from at least one virus strain, collecting hyperimmune bovine colostrum comprising immunoglobulins effective against the antigen protein of various strains of the virus, preparing whey from the colostrum, isolating the immunoglobulin molecules from the whey, and preparing an immunoglobulin preparation for use as an intranasal treatment. One aspect of the invention is to produce SARS-CoV-2 spike protein specific hyperimmune bovine colostrum comprising a high concentration of anti-SARS-CoV-2 antibodies. An intranasal delivery system for diminishing risk of SARS-CoV-2 infections in humans is provided.Type: ApplicationFiled: March 14, 2022Publication date: September 5, 2024Inventors: Mario PLAAS, Karin KOGERMANN, Eva ZUSINAITE, Toomas TIIRATS, Birgit AASMÄE, Ants KAVAK, Väinö POIKALAINEN, Lembit LEPASALU, Sander PIISKOP, Siimu ROM, Ruth OLTJER, Kadri KANGRO, Eve SANKOVSKI, Joachim GERHOLD, Anu PLANKEN, Raini PERT, Andres MÄNNIK, Andres TOVER, Mihhail KURASIN, Mart USTAV, Mart USTAV, Jr., Kiira GILDEMANN
-
Publication number: 20240293540Abstract: The disclosure features compositions and methods for increasing the half-life of a therapeutic agent (e.g., a C5 antagonist) in the serum of a subject (e.g., a human). Also featured are compositions and methods for: (i) decreasing the frequency by which a therapeutically effective amount of a therapeutic agent must be administered to a human having, suspected of having, or at risk for developing, a medical condition for which the therapeutic agent is effective and (ii) decreasing the dosage of the therapeutic agent required for therapeutic efficacy in a human having, suspected of having, or at risk for developing, a medical condition for which the therapeutic agent is effective. The methods include reducing the serum concentration of the antigen to which the therapeutic agent binds.Type: ApplicationFiled: October 6, 2023Publication date: September 5, 2024Inventors: Jeffrey William HUNTER, Paul P. TAMBURINI
-
Publication number: 20240293541Abstract: The present invention relates to a Leukocyte-specific protein 1 (LSP1)-deficient T cell-based anticancer immunotherapy. According to the present invention, tumor growth, tumor volume and size were reduced by means of LSP1 knockout, and LSP1 deficiency in T cells increases the number, distribution frequency, migration, and invasion of T cells, and increases the production of an anti-tumor cytokine to inhibit tumor growth and enhance tumor-killing ability. Thus, the present invention can be used for T cell-based immunotherapy.Type: ApplicationFiled: May 26, 2021Publication date: September 5, 2024Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Wan-Uk KIM, Riri KWON, Naeun LEE
-
Publication number: 20240293542Abstract: Provided is pharmaceutical composition for preventing or treating degenerative brain disease, containing regulatory T cells as an active ingredient. The pharmaceutical composition inhibits M1 microglial activation or transformation into DAM, promotes M2 polarization, inhibits tau protein phosphorylation, and increases the expression of anti-inflammatory cytokines, thereby protecting nerve cells, and thus it may be useful for the prevention or treatment of degenerative brain diseases.Type: ApplicationFiled: March 13, 2024Publication date: September 5, 2024Inventors: Seungwon LEE, Jae Yoon KIM, Hyung Joon KIM, Hyeonwoong PARK
-
Publication number: 20240293543Abstract: Edited cells, e.g., genomically edited cells, with reduced levels of immune rejection and/or improved persistence are described.Type: ApplicationFiled: June 23, 2022Publication date: September 5, 2024Inventor: John Anthony Zuris
-
Publication number: 20240293544Abstract: The technology relates in part to binding molecules that specifically bind to a polypeptide that is the Isoform 2 of mesotheiin, or that specifically bind to an antigenic determinant (epitope) of the isoform 2 of mesotheiin, or that specifically bind to polypeptides containing an antigenic determinant (epitope) of the isoform 2 of mesotheiin, chimeric PD1 receptors that bind to PD ligands such as PDLs, to polynucleotides including vectors that encode such binding molecules, to ceils presenting such binding molecules and to methods of making such cells, to humanized forms of the binding molecules, and to methods of using such binding molecules, such as for treating cancers (e.g., ovarian cancers and mesotheliomas), including cancers in which the Isoform 2 of mesotheiin is specifically expressed and/or upregulated relative to normal tissues.Type: ApplicationFiled: November 17, 2021Publication date: September 5, 2024Inventors: Lucia PICCOTTI, Leonardo MIRANDOLA, Maurizio CHIRIVA-INTERNATI, David SPENCER, Xiaohong WANG, Yibin CHEN
-
Publication number: 20240293545Abstract: Genetically engineered activated phagocytic cells are described and related vectors, compositions, methods and systems which allow efficient cell targeting through enhanced phagocytosis of target cells and treatment of conditions in an individual.Type: ApplicationFiled: April 23, 2021Publication date: September 5, 2024Inventors: Denise Montell, Abhinava K. Mishra, Alba Y. Torres Espinosa
-
Publication number: 20240293546Abstract: The present disclosure provides, in part, a novel chimeric antigen receptor (CAR) T cell that will simultaneously target wildtype EGFR (EGFRwt) and the vIII variant (EGFRvIII) and methods of making and using same.Type: ApplicationFiled: July 1, 2022Publication date: September 5, 2024Inventors: Peter FECCI, Darell BIGNER, Daniel LANDI, Daniel WILKINSON, Katherine RYAN
-
Publication number: 20240293547Abstract: Disclosed herein are compositions comprising polymeric perfluorocarbon nanoemulsions and methods of their production, as well as methods for their use in imaging, examination, diagnosis and/or treatment of neurological and psychiatric diseases, as well as for ultrasound-mediated localized drug release into the brain.Type: ApplicationFiled: October 19, 2023Publication date: September 5, 2024Inventors: Raag D. Airan, Qian Zhong
-
Publication number: 20240293548Abstract: The present invention is of using contact lenses for photodynamic inactivation of germs, a product, and a method of treating fungal keratitis by applying the same. The contact lens is to continuously release a photoactive solution containing a photosensitizer such as rose bengal and hydrogen peroxide to the ocular surface. The photosensitizer would be activated while these contact lenses are applied and exposed to daylight or other artificial lights in the environment. After activation, the photosensitizer will produce singlet oxygen and reactive oxygen species to inhibit the growth of fungi, thereby treating fungal keratitis without having the patient experiences eye pain or discomfort. Moreover, since the photoactive solution excludes any antifungal agents, the contact lenses for photodynamic inactivation of germs of the present invention can not only improve drug-resistant fungal keratitis but also prevent the germs from developing antimicrobial resistance.Type: ApplicationFiled: November 10, 2023Publication date: September 5, 2024Inventors: Tak-Wah WONG, Jia-Horung HUNG
-
Publication number: 20240293549Abstract: The invention relates to a conjugate of a protein or peptide with a therapeutic, diagnostic or labelling agent, said conjugate containing a protein or peptide bonding portion and a polyethylene glycol portion; in which said protein or peptide bonding portion has the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W? represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which said polyethylene glycol portion is or includes a pendant polyethylene glycol chain which has a terminal end group of formula —CH2CH2OR in which R represents a hydrogen atom, an alkyl group, or an optionally substituted aryl group. Also claimed are a method for making such a conjugate, and novel reagents useful in that method.Type: ApplicationFiled: March 19, 2024Publication date: September 5, 2024Applicant: POLYTHERICS LIMITEDInventors: Antony Godwin, Mark Frigerio
-
Publication number: 20240293550Abstract: Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.Type: ApplicationFiled: December 26, 2023Publication date: September 5, 2024Inventors: Anastasia Khvorova, Matthew Hassler, Julia Alterman, Bruno Miguel da Cruz Godinho
-
Publication number: 20240293551Abstract: A use of one or more lipid compounds in the delivery of nucleic acids, and a lipid nucleic acid mixture, pharmaceutical composition or kit comprising the lipid compounds and nucleic acids. The lipid compounds can promote the absorption, particularly oral absorption, of nucleic acids, and promote entry of nucleic acids into target sites in a subject in need thereof.Type: ApplicationFiled: July 27, 2022Publication date: September 5, 2024Inventors: Chengyu JIANG, Xinyi DU
-
Publication number: 20240293552Abstract: Provided herein are compositions or compounds comprising ionic liquids and therapeutic proteins or peptides, and methods of use thereof for the treatment of diseases or disorders.Type: ApplicationFiled: February 16, 2024Publication date: September 5, 2024Inventors: Tyler BROWN, Kelly IBSEN
-
Publication number: 20240293553Abstract: Provided are novel P-selectin inhibitors, compositions and uses thereof, and methods of making thereof.Type: ApplicationFiled: September 22, 2022Publication date: September 5, 2024Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Elliot Chaikof, Appi Mandhapati, Simon Park, Richard D. Cummings
-
Publication number: 20240293554Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.Type: ApplicationFiled: January 16, 2024Publication date: September 5, 2024Inventors: Christopher Scott NEUMANN, Kathleen OLIVAS, Robert LYON, Kung-Pern WANG
-
Publication number: 20240293555Abstract: This disclosure provides compositions, systems, and methods for the delivery of therapeutic oligonucleotides. The oligonucleotide is conjugated to a functional moiety comprising a carbohydrate. In certain embodiments, the carbohydrate is a glucosamine or a derivative thereof.Type: ApplicationFiled: December 12, 2023Publication date: September 5, 2024Inventors: Anastasia Khvorova, Ken Yamada, Vignesh Narayan Hariharan, Ananth Karumanchi
-
Publication number: 20240293556Abstract: Provided herein are carbohydrate derivatives of general formula (I) bearing a trans-cyclooctene moiety usable in covalently binding active moieties to cell surfaces in vitro and/or in vivo and their use for therapeutic or nontherapeutic purposes. Furthermore, compounds of general formula (II) are used together with the derivatives of general formula (I) in a method of binding active moieties to the cell surface. The compounds may be combined to form a kit for forming a covalent attachment of active moieties to the cell surface.Type: ApplicationFiled: June 20, 2022Publication date: September 5, 2024Inventors: Milan VRABEL, Rastislav DZIJAK, Anna KOVALOVA
-
Publication number: 20240293557Abstract: Proteolysis-targeting chimeras (PROTACs) that indirectly inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.Type: ApplicationFiled: June 8, 2022Publication date: September 5, 2024Inventors: Steven Fletcher, Alexandria Marie Carlson
-
Publication number: 20240293558Abstract: The present application provides conjugates of protein-binding ligands, in particular G12D mutant KRAS ligands, with ubiquitin ligase ligands and methods for treating diseases such as cancer.Type: ApplicationFiled: June 15, 2022Publication date: September 5, 2024Inventors: Hengmiao CHENG, Jean-Michel VERNIER, Ping CHEN
-
Publication number: 20240293559Abstract: Provided is the following compound or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, polymorphic substance, solvate, N-oxide, isotope-labeled compound, metabolite, chelate, coordination complex, inclusion compound or prodrug thereof, and a pharmaceutical composition comprising the compound. Also provided is an application of the compound in preparing a drug for a disease associated with SHP2 phosphatase. Also provided is a method for treating a disease associated with SHP2 phosphatase.Type: ApplicationFiled: April 8, 2024Publication date: September 5, 2024Inventors: Wenming LI, Xiaobo LI, Peng LU, Mingnan PIAO, Ning WANG, Guokun YU, Junrong LIU, Yu ZHANG, Tiantian YU
-
Publication number: 20240293560Abstract: Polyoxazoline (POZ) conjugates wherein the conformation of the POZ conjugate and the release rate of an agent from the POZ conjugate can be controlled by selecting one or more characteristics of the POZ polymer and methods of controlling the conformation of a POZ conjugate and the release rate of an agent prior are provided as well as methods of treatment using such POZ conjugates and methods. Pharmaceutical compositions including a POZ conjugate are also provided.Type: ApplicationFiled: May 3, 2024Publication date: September 5, 2024Applicant: Serina Therapeutics (AL), Inc.Inventors: J Milton HARRIS, Michael D BENTLEY, Tacey X VIEGAS, Randall W MOREADITH, Zhihao FANG, Kunsang YOON, Rebecca WEIMER
-
Publication number: 20240293561Abstract: The present invention provides a BBB-permeable multifunctional system for the synchronized delivery of distinct active agents to the brain. The multifunctional system is based on an inorganic core particle which is conjugated through a first polymeric linker to a first active agent; through a second polymeric linker to a second active agent; and through a third polymeric linker to a brain-internalizing transporter moiety. Further provided are a process for preparation of the multifunctional system, pharmaceutical compositions comprising the multifunctional system and uses thereof in therapeutic and/or diagnostic methods.Type: ApplicationFiled: July 13, 2022Publication date: September 5, 2024Inventors: Rachela POPOVTZER, Oshra BETZER, Yuval SAGIV, SAGIV, Revital MANDIL-LEVIN, Adam A. ANTEBI
-
Publication number: 20240293562Abstract: Neurotrophin receptor binding conjugate compositions for treating a neurological condition (e.g., neuroinflammation caused by or associated with the neurological condition) are provided. Methods according to certain embodiments include administering to subject in need thereof an active agent conjugate that includes one or more active agent compounds for treating the neurological condition (e.g., neuroinflammation caused by or associated with the neurological condition) covalently bonded to a protein, peptide or peptidomimetic that binds selectively to a neurotrophin receptor. In certain embodiments. the active agent conjugate facilitates one or more of endocytosis, axonal transport and pharmacological activity in the neuronal cell body, such as when the active agent conjugate is administered to the subject intranasally. Kits for administering the active agent conjugate, such as intranasally, intracisternally or intravitreally are also described.Type: ApplicationFiled: November 30, 2021Publication date: September 5, 2024Inventors: CONSTANCE A. MCKEE, STEPHEN B. KAHL, LOUIS EUGENE BURTON, GORDON CRAIG HILL
-
Publication number: 20240293563Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.Type: ApplicationFiled: February 23, 2024Publication date: September 5, 2024Inventors: Brett P. MONIA, Thazha P. PRAKASH, Garth A. KINBERGER, Richard LEE, Punit P. SETH, Michael OESTERGAARD, Mehran NIKAN, Shalini ANDERSSON, Eva Carina AMMALA, Daniel Laurent KNERR, Maria OLWEGARD-HALVARSSON, William John DRURY, III, Eric VALEUR
-
Publication number: 20240293564Abstract: The invention described herein relates to methods and compositions for treating cancer in a patient, or a tumor cell, by administering an effective amount of an antibody-anti-fugetactic agent complex.Type: ApplicationFiled: February 6, 2024Publication date: September 5, 2024Inventor: Mark C. Poznansky
-
Publication number: 20240293565Abstract: Provided is an anti-HER3 antibody, or an antibody drug conjugate (ADC) containing the anti-HER3 antibody. Also provided is the use of the antibody or ADC in the treatment of HER3-expression cancers.Type: ApplicationFiled: June 15, 2022Publication date: September 5, 2024Applicant: BEIJING SINOTAU BIO-PHARMACEUTICALS TECHNOLOGY CO., LTD.Inventors: Xiaoyan ZHONG, Zhe Li, Jie ZHU
-
Publication number: 20240293566Abstract: The present disclosure provides antibody-drug conjugates (ADCs) comprising antibodies that bind to the class III variant of EGFR (EGFRVIII) conjugated to tesirine, and methods of using the same. According to certain embodiments, the antibodies or antigen-binding fragments thereof, useful herein, bind human EGFRVIII with high affinity. The antibodies or antigen-binding fragments thereof, useful herein, may be fully human antibodies. The ADCs provided herein are useful for the treatment of various cancers.Type: ApplicationFiled: June 21, 2022Publication date: September 5, 2024Inventors: Frank DELFINO, Marcus KELLY, Jessica KIRSHNER, Thomas NITTOLI, Gavin THURSTON
-
Publication number: 20240293567Abstract: Desired is development of novel CDN derivatives having STING agonist activity; and a therapeutic agents and/or therapeutic methods using the novel CDN derivatives for diseases associated with STING agonist activity. Further desired is development of a therapeutic agents and/or therapeutic methods capable of delivering the novel CDN derivatives specifically to targeted cells and organs for diseases associated with STING agonist activity. The present invention provides novel CDN derivatives having potent STING agonist activity, and antibody-CDN derivative conjugates including the novel CDN derivatives.Type: ApplicationFiled: April 22, 2024Publication date: September 5, 2024Applicant: Daiichi Sankyo Company, LimitedInventors: Toshifumi TSUDA, Toshiki TABUCHI, Hideaki WATANABE, Hiroyuki KOBAYASHI, Masayuki ISHIZAKI, Kyoko HARA, Teiji WADA, Masami ARAI
-
Publication number: 20240293568Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.Type: ApplicationFiled: May 1, 2024Publication date: September 5, 2024Applicant: Dyne Therapeutics, Inc.Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
-
Publication number: 20240293569Abstract: Provided herein are a linker compound, a linker-drug conjugate where the linker compound is conjugated to a drug, an antibody-drug conjugate where a drug is conjugated to an antibody or an antigen binding fragment thereof via the linker compound, and a method for treating cancer by administering the antibody-drug conjugate to a subject in need thereof.Type: ApplicationFiled: February 9, 2024Publication date: September 5, 2024Applicant: PINOTBIO, INC.Inventors: Doo Young JUNG, Hyun Yong Cho, Gangadhar Rao Mathi
-
Publication number: 20240293570Abstract: A drug link assembly unit has a specific linker structure. Connecting the drug link assembly unit to an antibody forms a targeted linker-drug conjugate. The targeted linker-drug conjugate having the specific linker structure is low in polymer content and naked antibody percentage and proper in DAR value, exhibits excellent plasma stability, storage stability and anti-tumor effect, and has a wide application prospect in preparation of drugs for preventing and/or treating tumors.Type: ApplicationFiled: April 10, 2024Publication date: September 5, 2024Inventors: Jinkun HUANG, Chenglong WU, Chaoyang FENG
-
Publication number: 20240293571Abstract: Disclosed are brain-targeted antibody delivery systems, methods of forming the systems, and methods of using the systems. The systems include hydrophilic nanogels based upon poly(ethylene glycol) copolymers. The nanogels can encapsulate an antibody for delivery to the brain and can include ligands for blood brain barrier (BBB) receptors on the surface, and as such, can utilize a systemic route of administration for delivery of the antibody to the brain and the eye. The systems can be utilized for systemic delivery routes to deliver the antibody to the brain side of the blood brain barrier and inside glial cells and degrade its corresponding protein. The systems can be utilized in treatment of neurodegenerative or retinal disorders.Type: ApplicationFiled: March 3, 2022Publication date: September 5, 2024Inventors: PEISHENG XU, MINGMING WANG
-
Publication number: 20240293572Abstract: In some aspects, the present disclosure provides therapeutic-agent-releasing polyamino compounds that comprise a polyamino moiety that is covalently linked to a residue of a hydroxyl-substituted therapeutic agent by an ester bond. In various embodiments, such therapeutic-agent-releasing polyamino compounds are used to form therapeutic-agent-releasing hydrogels. In other aspects, the present disclosure provides therapeutic-agent-releasing polysaccharides that comprise a plurality of hydroxyl-substituted therapeutic agent residues that are covalently linked to a carboxylic-acid-containing polysaccharide along a backbone of the carboxylic-acid-containing polysaccharide.Type: ApplicationFiled: February 28, 2024Publication date: September 5, 2024Applicant: Boston Scientific Scimed, Inc.Inventors: Yen-Hao Hsu, Cristian Parisi, Joseph Thomas Delaney, JR.
-
Publication number: 20240293573Abstract: Provided are a phospholipid-photothermal nanoparticle having a cancer cell surface-specific antibody bound to the surface thereof, which can specifically bind to cancer cells, has a small particle size and excellent stability, and can effectively induce cancer cell apoptosis by exerting a photothermal effect when irradiated with near-infrared rays, and wherein the antibody or a fragment thereof is site-specifically conjugated to the phospholipid-photothermal nanoparticle, and thus the cancer cell binding ability and the photothermal cancer therapeutic effect of the phospholipid-photothermal nanoparticle are improved, and the phospholipid-photothermal nanoparticle having an antibody bound to the surface thereof are advantageously utilized for cancer therapy.Type: ApplicationFiled: March 8, 2021Publication date: September 5, 2024Applicant: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATIONInventors: Yu-Kyoung OH, Young Kee SHIN, Gayong SHIM, Hobin YANG, Quoc Viet LE